Research
Hormonal
Conjugated Linoleic Acid (CLA) shows potent anti-carcinogenic and anti-lipogenic effects in animal models, but human evidence is currently insufficient to confirm these benefits at typical dietary intakes.
Do not rely on CLA supplements for fat loss or cancer prevention based on current evidence. The doses required to see benefits in animals are much higher than what humans typically eat or can safely supplement. Focus on whole foods like dairy and meat which contain natural CLA, but do not expect therapeutic effects from supplementation.
ModerateQualifiesMEDIUM confidence
Interest in the levels of CLA in the human diet have increased in recent years because of accumulating evidence, largely based on animal studies, which suggest potential health benefits of CLA... Whether such effects are present in humans... remains to be determined.
Why this rating
Strong animal data, weak/inconclusive human data.
Source
Dietary fatty acids and human health
Christine M. Williams · Annales de Zootechnie · 2000
DOI 10.1051/animres:2000116
narrative_reviewCited 643×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-chain omega-3 fatty acids (EPA and DHA) provide cardiovascular protection through anti-atherogenic, anti-thrombotic, and anti-inflammatory mechanisms, with benefits observed at intakes around 1g/day.Strong
- High intake of trans fatty acids (TFA) increases the risk of coronary heart disease (CHD) by raising LDL cholesterol and lowering HDL cholesterol, a dual adverse effect not shared by saturated fatty acids.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →